From April 1st, 2020, EuroEyes Shanghai and Beijing clinics offer a new service for our patients: diabetic retinopathy screening. By equipping clinics with the latest Zeiss OCT technology and OCTA devices, EuroEyes China will fulfill even more comprehensively the demand in China for the treatment of retinal diseases.
Data shows that 1 in 11 Chinese people suffer from diabetes. It is predicted that by 2040, the diabetic population in China will reach 151 million. All types of diabetes carry the risk of developing diabetic retinopathy.
Patients may know that a healthy diet helps control blood pressure and blood sugar, but most of them don't realise that diabetes can seriously harm their eyes, gradually and irreversibly.
With the help of Zeiss OCT AngioPlex device, doctors at EuroEyes can obtain super-high-resolution images of the retina and retinal vessels in a few seconds. It is a non-invasive eye check for patients without injecting contrast medium, but can detect certain fundus diseases at a very early stage, and allows early intervention for conditions such as diabetic retinapathy and age-related macular degeneration.
In China, EuroEyes targets Shanghai and Beijing as the first two local markets. By offering the high-end new service with cutting-edge technologies, EuroEyes will help more patients with retinal diseases in China.
The EuroEyes Clinic Group is a globally successful company that was founded 26 years ago in Hamburg and still has its headquarters there today. In addition to locations throughout Germany, EuroEyes is also represented in China and Denmark. The company offers patients the full range of refractive surgery for the correction of visual disorders. Using state-of-the-art eye laser and lens surgery procedures, EuroEyes treats more than 25,000 patients each year with nearsightedness, farsightedness, astigmatism, presbyopia or cataracts. The treatment enables the start of a life free of glasses and contact lenses without any visual impairment.